HbA1c serves as a useful and accessible biomarker for vascular risk stratification in patients undergoing carotid endarterectomy.
Does HbA1c predict long-term cardiovascular outcomes in patients undergoing carotid endarterectomy?
HbA1c may serve as a useful biomarker for long-term vascular risk stratification in patients undergoing carotid endarterectomy.
HbA1c appears to be a useful, accessible biomarker for vascular risk stratification in patients undergoing CEA.
Pinheiro-Silva et al. (2026) studied this question. HbA1c serves as a useful and accessible biomarker for vascular risk stratification in patients undergoing carotid endarterectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: